Going anti-Viral

In episode 49 of Going anti-Viral, Dr Judith Currier joins host Dr Michael Saag to discuss Next-Gen HIV Prevention and Treatment. Dr Currier is a Professor of Medicine at UCLA and has more than 25 years of experience in the design, implementation, conduct, and analysis of clinical trials to optimize antiretroviral management of HIV and related complications. Dr Currier and Dr Saag provide an overview of why new antiretroviral drugs are needed and discuss the successful return on investment in biomedical research. They also provide a detailed review of long-acting antiretroviral drugs and discuss the state of current research for new options, including a discussion of lenacapavir. Finally, they share their concerns for what is at stake if attempts to cut the federal research budget are successful and the disruption it will bring to the progress that has been made in HIV care and other viral diseases.  0:00 – Introduction1:20 – Overview of why new antiretroviral drugs are needed2:57 – The return on investment in biomedical research3:52 – Overview of the need for long-acting antiretroviral drugs and options available 8:23 – Review of the current research and prospects for new long-acting therapies 12:59– Discussion of lenacapavir and the potential benefits for prevention and treatment 14:21 – Summary of other drugs on the horizon that may be potential treatments18:39 – Overview of the different methods for delivery of drugs21:11 – Impact of potential budget cuts on HIV research, on people with HIV, and on other viral diseases __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Mary Fisher joins host Dr Michael Saag to discuss Communicating the Importance of Science and Research to the Public. Ms Fisher is an artist, author, and activist, who has spent a lifetime giving voice to the voiceless. Her historic speech at the 1992 Republican Convention, A Whisper of AIDS, has been named one of “forty famous speeches that have had long-term effect on society.” In this episode, Ms Fisher discusses her history of activism including her work in Africa before and after the arrival of PEPFAR and the concern for the many communities she worked with given the termination of USAID. Ms Fisher also discusses her new book Uneasy Silence: An activist seeks justice and courage over a lifetime of change where she and Dr Saag stress the importance of speaking out for scientific research given the impact it has on patient care and saving lives. 0:00 – Introduction1:17 – History of Ms Fisher's activism 4:11 – Impact of Ms Fisher's work in Africa and discussion of the quality of life before and after PEPFAR 10:05 – The impact of the elimination of USAID on people with HIV, nutrition, and other diseases 14:36 – Discussion of Ms Fisher's book Uneasy Silence: An activist seeks justice and courage over a lifetime of change20:12 – Why scientific research is important and the impact of cuts to the research budget at NIAID28:55 – The need to speak out for science, the practice of medicine, and care for those in need of careRelated Resources:Uneasy Silence: An activist seeks justice and courage over a lifetime of change Amazon  A Whisper of AIDS YouTube Project Angel FoodEpisode 43 YouTube | Apple Podcasts with Dr Izukanji SikazweVoices in HIV Research and Global Health, from the Scientists, the Labs, and the Community YouTube __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going Anti-Viral, Rebecca Denison joins host Dr Michael Saag as a follow-up discussion to her Martin Delaney presentation at CROI 2025: 40+ Years of HIV: What's Changed, What Hasn't, What Shouldn't, What Must. Ms Denison is an HIV-positive writer, educator, mother, and founder of WORLD, Women Organized to Respond to Life-threatening Diseases. Dr Saag and Ms Denison reflect on her history of living with HIV and her 40 + years as an HIV activist. They discuss the impact that recent cuts at USAID and PEPFAR are having international efforts to reduce HIV transmission and the loss in trust in healthcare practitioners since programs have been terminated. They also discuss concerns about cuts to federal funding for HIV care programs in the US and the impact of recent loss of staff expertise at federal agencies. Finally, Dr Saag and Ms Denison ask all care clinicians to share their stories to their communities as a way of becoming advocates for the importance of HIV care.0:00 – Introduction2:41 – History of Ms Denison's activism in HIV and AIDS 4:58 – Discussion of the gap in HIV care since the termination of USAID and PEPFAR contracts8:29 – The loss of trust in global HIV health care practitioners and stories of growing HIV transmission since funding for care has been terminated14:24 – Risks of funding cuts to domestic HIV care programs and Medicaid18:02 – How a younger generation of advocates can learn from the history of HIV activism19:51 – The message sent by the reorganization of HHS and the dismissal of leading HIV experts22:06 – How clinicians can be an advocates for HIV care Watch/Listen to related episodes:Special Episode YouTube | Apple Podcasts 40+ Years of HIV: What's Changed, What Hasn't, What Shouldn't, What Must. The Martin Delaney presentation at CROI by Rebecca DenisonEpisode 43 YouTube | Apple Podcasts Innovations in HIV Service Delivery with Dr Izukanji Sikazwe__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going Anti-Viral, Dr Raymond Schinazi joins host Dr Michael Saag for an in-depth conversation about the development of a cure for hepatitis C. Dr Schinazi, the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University, shares insights from his distinguished career in antiviral research and development. He begins by outlining his background and long-standing interest in antiviral therapies, including groundbreaking work in HIV treatment. The conversation then shifts to his pivotal role in the development of sofosbuvir, a breakthrough direct-acting antiviral drug in the cure for hepatitis C, and the importance of NS5A inhibitors in antiviral drug regimens. Dr Schinazi also offers a rare behind-the-scenes look at the business and regulatory journey of bringing a transformative therapy to market, reflecting on the personal impact of this milestone. The episode concludes with a discussion of his current research into potential treatments for hepatitis B. 0:00 – Introduction1:24 – Overview of Dr Schinazi's background and his interest in antiviral therapy2:56 – Discussion of Dr Schinazi's work in the development of antiviral agents for HIV4:45 – Background on the development of sofosbuvir for the cure of hepatitis C10:01 – The role of NS5A inhibitors in treatment12:42 – History of bringing hepatitis C treatment to market14:25 – Discussion of the effectiveness of NS5A inhibitors 16:49 – The risk of reinfection and review of the basic science behind pharmaceuticals for hepatitis C18:22 – How the discovery of a hepatitis C cure impacted Dr Schinazi personally25:16 – Overview of Dr Schinazi's current research in Hepatitis B__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Graham Hatfull, a Professor of Biological Sciences at the University of Pittsburgh. Dr Hatfull joins Dr Saag to discuss Bacteriophages for the treatment of antimicrobial-resistant (AMR) bacterial infections. Dr Hatfull provides an overview of the types of bacteriophages and how they can be used to treat antimicrobial-resistant bacteria. Dr Hatfull and Dr Saag discuss the challenges of treating bacterial infections with phages given the diversity and complexity of the different types of bacteria and bringing phage treatments to scale. Finally, they discuss what research is needed to overcome the challenges of phage treatment and look to the future where technology enables synthetically produced phages to provide targeted therapy to antimicrobial resistant bacteria.0:00 – Introduction1:05 – Overview of bacteriophages and Dr Hatfull's interest in phage research2:46 – How phages can be used clinically for antimicrobial-resistant bacteria4:34 – Differences between the 2 types of phages: lytic phages and temperate phages6:01 – How phages are used to target specific types of bacteria9:37 – The challenge of phage treatment matching and natural CRISPR processes within bacteria15:16 – Understanding the phage genome diversity 18:59 – Discussion of therapeutic uses of phages28:32 – Prospect of phages for future treatments including synthetic phagesResources: Harnessing the Power of Bacteriophages with Dr Robert Schooley:YouTube: https://youtu.be/_BUpDRNhMsQApple Podcasts: https://podcasts.apple.com/us/podcast/episode-10-harnessing-the-power-of-bacteriophages/id1713226144?i=1000647215580 Exploring Bacteriophage Therapy for Drug-Resistant Bacterial Infections Robert T. Schooley, MD: https://www.iasusa.org/wp-content/uploads/2023/03/31-1-23.pdf  The inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics: https://www.iasusa.org/bacteriophage-conference/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Annemarie M. Wensing, a Clinical Virologist at the University Medical Center Utrecht and an Honorary Professor at the University of the Witwatersrand in Johannesburg. Dr Wensing joins Dr Saag to discuss the recently released IAS–USA 2025 Update of the Drug Resistance Mutations in HIV-1. Dr Wensing discusses the influence of Dr Charles Boucher in developing her interest in the topic of HIV drug resistance and Dr Wensing and Dr Saag provide an overview of HIV drug resistance and testing. Dr Wensing also provides advice to clinicians on how to manage patients who experience drug resistance. Dr Wensing and Dr Saag then discuss an upcoming report soon to be published that addresses the potential role and the important limitations of HIV DNA resistance testing. Finally, they address the topic of drug resistance in the absence of resistance mutations and look ahead to what the future holds for the field of HIV resistance. 0:00 – Introduction 1:30 – Dr Wensing reviews the influence that Dr Charles Boucher played in her development as an investigator and her interest in HIV resistance 2:46 – Discussion of why there is HIV drug resistance 4:48 – Overview of drug resistance testing, genotypes and phenotypes 7:25 – New recommendations from the IAS-USA resistance mutation panel 9:50 – Advice to clinicians on managing drug resistance 16:16 – Discussion of HIV DNA resistance testing 21:26 – Understanding drug failure in the absence of resistance mutations  24:49 – Predictions about the future Resources:  IAS–USA Drug Resistance Mutations Chart: https://www.iasusa.org/hiv-drug-resistance/hiv-drug-resistance-mutations/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Izukanji Sikazwe, the Chief Executive Officer for the Centre for Infectious Disease Research in Zambia (CIDRZ). Dr Sikazwe joins Dr Saag to provide an overview of her symposium presentation at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) entitled Innovations in HIV Service Delivery: Building a Path Forward with Those Left Behind. Dr Sikazwe discusses her career journey in treatment of HIV in Zambia and her path to CIDRZ. Dr Sikazwe and Dr Saag discuss the history of HIV and AIDS in Zambia and address the impact that PEPFAR had on the disease when it arrived in the country in 2004. They discuss how PEPFAR has operated in Zambia and provide a current overview of the sudden cancellation of USAID contracts on those receiving HIV care and treatment and other health services. Finally, they look ahead given the current disruptions on how Zambia and other countries can move forward to meet the needs of those in need of care.0:00 – Introduction1:41 – Dr Sikazwe reviews her path to CIDRZ5:21 – History of HIV and AIDS in Zambia and discussion of stigma7:53 – The impact of PEPFAR's arrival in Zambia and Dr Sikazwe's personal history with treatment during that time13:37 – How PEPFAR works in Zambia16:56 – Impact of recent decision by the US government to cancel USAID contracts22:31 – Disruption to other health services that USAID has supported in Zambia23:50 – Response from the government in Zambia24:46 – Status of HIV in Zambia prior to cancellation of USAID contracts25:50 – The best-case scenario for people living with HIV globally and closing remarksResources: CROI 2025: https://www.croiconference.org/Centre for Infectious Disease Research in Zambia (CIDRZ): https://www.cidrz.org/   PEPFAR: https://www.state.gov/pepfar/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

This episode of Going anti-Viral, features Rebecca Denison, who gave the Martin Delaney Presentation, entitled 40+ Years of HIV: What's Changed, What Hasn't, What Shouldn't, What Must, at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI). Ms. Denison is the founder of Woman Organized to Respond to Life-threatening Diseases or (WORLD).  Resources: CROI 2025: https://www.croiconference.org/Woman Organized to Respond to Life-threatening Diseases or (WORLD): https://womenhiv.org/Link to video of presentation: https://youtu.be/CutIwfkv8oUMore on the Martin Delaney Presentation: https://www.croiconference.org/presenters/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Tonia Poteat, a professor in the Duke University School of Nursing and co-director of the Duke SGM Wellness Program. Dr Poteat joins Dr Saag to provide an overview of a Themed Discussion session that she is leading at CROI 2025 entitled Meeting the Treatment and Prevention Needs of Transgender Women. Dr Poteat and Dr Saag address the 3 most common challenges faced in the care of transgender persons: uninformed clinicians, societal discrimination, and efforts by governments to limit the rights of transgender persons. They discuss efforts to educate clinicians and summarize the resources that are available to provide care to transgender persons facing stigma and discrimination. They also discuss efforts to take legal action against discriminatory policies. Finally, Dr Poteat and Dr Saag look ahead to the next five years of transgender care and provide advice to all involved in the care of transgender persons during a challenging time. 0:00 – Introduction1:26 – Overview of Dr Poteat's background and research interests3:42 – Most common challenges encountered by transgender women4:59 – Educating clinicians about care for transgender women9:46 – Resources for clinicians to learn about managing stigma and discrimination11:24 – Efforts by governments to limit transgender care16:14 – Overview of the Themed Discussion session at CROI 202519:07 – Looking ahead to the next five years in transgender careResources: CROI 2025: https://www.croiconference.org/IAS-USA webinar: Gender-Affirming Hormone Care for People With HIV: https://www.iasusa.org/events/webinar-2024-poteat/AIDS Education and Training Center: https://aidsetc.org/  World Professional Association for Transgender Health: https://wpath.org/  Trans Lifeline: https://translifeline.org/ Trevor Project: https://www.thetrevorproject.org/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Joseph Eron, Professor of Medicine at University of North Carolina (UNC) about the topic of his upcoming presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025: HIV Cure Research: State of the Art and Navigating Presentations at CROI 2025. Dr Eron discusses the state of HIV cure research including a detailed discussion of why it has been so difficult to develop a cure for HIV. Dr Saag and Dr Eron discuss the difference between HIV cure and functional cure and provide a detailed overview of cure research efforts looking at blocking and locking HIV in human DNA. Dr Saag and Dr Eron also discuss the potential for “molecular scissors” (CRISPR-Cas9) to cure HIV. Finally, they provide an overview of cure research that will be presented at CROI, highlighting the plenary presentation by Dr Ole Søgaard at CROI on Monday March 10 entitled HIV Cure: A Translational Research Perspective. For more information about the topic of this episode, listen to an earlier episode of Going anti-Viral where Dr Saag discusses Vaccine Development with Dr Richard Koup, see links in the resources below. 0:00 – Introduction1:31 – Defining cure in the context of HIV4:56  – Why is it so hard to cure HIV7:56 – What is functional cure11:47 – Description of the concept of “block and lock” in human DNA14:33 – Discussion of tat inhibitors – blocking of HIV regulatory genes18:02 – Prospect of using “molecular scissors” (CRISPR-Cas9) as a cure23:13 – Highlights in HIV cure research at CROI and closing remarksResources: CROI 2025: https://www.croiconference.org/Going anti-Viral Episode 4 – A Deep Dive into Vaccine Development with Dr Richard Koup: Apple Podcasts: https://podcasts.apple.com/us/podcast/episode-4-a-deep-dive-into-vaccine-development-with/id1713226144?i=1000637677124 YouTube: https://youtu.be/nXeMt3GMj4Q __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Diane Havlir, Professor of Medicine at the University of California San Francisco. Dr Havlir currently serves as Chair of the Scientific Program Committee for the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) and joins Dr Saag to provide a preview of CROI 2025. Dr Havlir provides an overview and history of CROI along with a summary of how the program is developed. Dr Saag and Dr Havlir review why CROI is unique among scientific meetings: leading scientific advances, poster sessions, and the focus on supporting new investigators. They also discuss expected hot topics from CROI such as: HIV treatment and cure, STI prevention, weight management, aging and HIV, as well as pediatric and adolescent care. Dr Saag and Dr Havlir provide an overview of resources that will be available to those who will not attend CROI in person. Finally, they discuss the value of CROI during a challenging time for all involved in the field of HIV research, care, and treatment.0:00 – Introduction1:36 – Overview and history of CROI4:12 – What makes CROI unique6:21 – Discussion of how the CROI program is developed both abstract and invited presentations11:04 – How attendees can interact at CROI12:06 – Features of poster abstract sessions and poster hall13:42 – CROI focus on new investigators17:55 – Hot topics at CROI 202520:45 – Resources for people not attending CROI22:26 – Value of CROI during a challenging time and closing remarksCROI Resources: https://www.croiconference.org/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Andy Pavia of the University of Utah for an update on COVID-19. Dr Pavia and Dr Saag review COVID-19 cases and deaths in 2024 including a discussion about the reasons why deaths have declined compared with earlier years in the pandemic. They also review Long COVID and challenges clinicians face with treatment. Dr Pavia provides a detailed review of COVID-19 vaccines and effectiveness including recommendations on who should be vaccinated. Dr Saag and Dr Pavia review COVID-19 testing, including home testing and antiviral (including monoclonal antibody) treatments. They also discuss how best to provide early treatment to persons at high risk of developing severe disease. Finally, they provide predictions for the future including possible improvements in next generation of COVID-19 vaccines.0:00 – Introduction1:21 – COVID-19 cases and deaths in 20243:21 – Discussion of reduction in deaths 5:11 – Evolution of COVID-19 immunity and discussion of Long COVID12:37 – Challenges in treating Long COVID16:20 – Review of data on effectiveness of COVID-19 vaccines and current recommendations on who should receive a vaccine19:10 – Recommendations on use of antiviral treatments and testing – including recommendations for persons at high risk for developing severe disease23:16 – Discussion of use of remdesivir24:44 – Recommendations for use of pemivibart in persons who are immune compromised 26:30 – Predictions for future therapies and vaccines 28:11 – Summary and closing remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Melanie Thompson who is a clinical researcher and provider of HIV clinical care in Atlanta, Georgia. As Principal Investigator and Executive Director of the AIDS Research Consortium of Atlanta (ARCA), she has led over 400 studies of HIV treatment and prevention and is recognized as an expert in the treatment of patients with HIV. In the episode, Dr Thompson and Dr Saag discuss the recently released 2024 update of primary care guidance for providers who care for persons with HIV by the HIV Medicine Association of the Infectious Diseases Society of America (see links in resources below). They address topics such as telemedicine, outreach to underserved populations, and how to create a welcoming clinic to improve retention in care. They discuss how HIV providers have been leaders in primary care in areas like hepatitis and address how to bring future generations of providers into HIV medicine. Finally, they address the importance of providers being advocates to their elected representatives about HIV medicine and that providing care to individuals, no matter who they are and where they come from, improves overall public health.0:00 – Introduction1:30 – A discussion of Dr Thompson's background in HIV medicine and transition from primary care to focus on HIV4:54 – What's new in the recently released primary care guidelines for persons with HIV 8:40 – Discussion of new recommendations in how providers can manage outreach, including providing mobile care to individuals with substance use disorder and unstable housing15:15 – Treatment of hepatitis as an example of how HIV medicine has led the way in providing primary care 17:04 – Review of guidance on substance use disorder including the use of Narcan and Buprenorphine19:14 – Reflections on the importance of providers being advocates to their elected representatives  24:10 – A discussion of how to create a future generation of HIV providers whether from internal medicine or infectious diseases, or both28:05 – Closing remarks  ResourcesHIV Medicine Association - https://www.hivma.org/HIVMA/IDSA HIV Primary Care Guidance - https://academic.oup.com/cid/advance-arti__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

This episode of Going anti-Viral features an IAS–USA Dialogue titled "Latest Update on Urgent Viral Outbreaks," a panel discussion held on January 15, 2025. This IAS-USA Dialogue is a must listen as our distinguished panel of infectious diseases experts dives deep into some of the most pressing public health challenges facing the world today. Moderated by Carlos del Rio, MD, a Distinguished Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine, this Dialogue brings together world-class experts Yvonne Maldonado, MD, Peter Chin-Hong, MD, and Jason Zucker, MD, to discuss the latest news on urgent and emerging viral outbreaks, including mpox, avian flu (H5N1), respiratory syncytial virus (RSV), measles, human metapneumovirus, and COVID-19/long COVID.The panel also reflects on the alarming erosion of public trust in public health experts, which has been compounded by misinformation and the long-term effects of the COVID-19 pandemic. 0:00 – Introduction 2:27 – Update on mpox including treatment options11:09 – Discussion of avian flu (H5N1), influenza, and vaccination in human and animals27:36 – Impact of avian flu (H5N1) on dairy and other agriculture industries and the role of public health in supporting the economy32:47 – Impact of recent study on Tamiflu in treatment recommendations and discussion of Biloxivir37:37 – Update on COVID-19 – vaccination, treatment with Paxlovid, other treatment options, and long COVID48:27 – Recent updates on respiratory syncytial virus (RSV) and vaccination 52:03 – Discussion of human metapneumovirus54:25 –Impact of misinformation on the reduction in measles vaccinations and the health risks of measles to the population at large 59:54 – Concluding remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Laura Cheever who was, until recently, the Associate Administrator of the HIV/AIDS Bureau at the Health Resources and Services Administration (HRSA). She joined HRSA in 1999 when she served as the national director of the Ryan White AIDS Education and Training Center program. Dr Cheever is Board Certified in Infectious Diseases and continues to provide clinical care for patients with HIV. Dr Cheever describes her early work at HRSA and the Ryan White HIV/AIDS Program. Dr Cheever and Dr Saag then discuss quality measures adopted to demonstrate program effectiveness and the impact these efforts had on funding. They also discuss the staff in the program and their role in working with local providers. They address the role that private insurance, the Affordable Care Act, and different presidential administrations play in the services of the program as well as work left to be done and look ahead to the next ten years of HIV care.0:00 – Introduction1:40 – A discussion of Dr Cheever's early years at the Health Resources and Services Administration (HRSA)7:51 – Implementation of national quality measures for HIV care using data collection through CAREWare11:41 – How did new information impact decision making regarding Ryan White funding decisions15:04 – Impact of changing guidelines on direction given to the Ryan White clinics19:26 – The staff at HRSA and the impact of potential budget cuts on the program24:05 – The role private insurance and the Affordable Care Act had in providing treatment through the Ryan White program 25:10 – Do different presidential administrations influence the services of the Ryan White program27:34 – Discussion of the work left to be done 29:29 – Predictions for the next ten years of HIV care and closing remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Kevin Carmichael of the Arizona Department of Health Services about the unique challenges caregivers faced in addressing the HIV/AIDS pandemic. Dr Carmichael is a family physician who began work in HIV in 1983 while in medical school in Miami, Florida. During his residency at the University of Miami, Dr Carmichael co-authored one of the first written guidance for clinical HIV care “HIV/AIDS: A Primary Care Handbook.” Dr Saag and Dr Carmichael discuss their shared history in caring for people during the early years of HIV and AIDS in the 1980s and 1990s. They also discuss the challenges in managing families of people with AIDS. Dr Carmichael then reflects upon the transition in the care of HIV in 1995 when protease inhibitors became available, effectively the start of turning HIV into a manageable chronic disease. Finally, Dr Saag and Dr Carmichael provide thoughts for younger practitioners currently involved in HIV management.0:00 – Introduction1:22 – A discussion of the early years of HIV and AIDS care in the 1980s7:43 – How Dr Carmichael came to focus on HIV and AIDS care12:36 – Dr Carmichael's transition to care in Arizona and differences from his time in Miami16:08 –Discussion of advanced AIDS and working with families of people with HIV at the time23:12 – The arrival of protease inhibitors in 1995 and the transition to management of a chronic disease31:00 – Closing remarks and reflections for younger practitioners involved in HIV care __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Episode 33 - Overview of Travel Medicine: Vaccines, Outbreaks, and More - Dr David Freedman In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr David Freedman of the University of Alabama at Birmingham to provide an overview of travel medicine: vaccines, outbreaks, and more. Dr Freedman is a professor of infectious diseases and his research is focused on clinical tropical medicine, including the development of surveillance networks to characterize infectious disease morbidity in travelers and migrants. Dr Saag and Dr Freedman provide an overview of worldwide outbreaks such as: mpox, H5N1, Marburg virus, Ebola, dengue fever, chikungunya, and Zika virus. Dr Freedman discusses the treatments and vaccines available for each of these outbreaks. They also address the clinical challenges of treating individuals with emerging infections of unknown origin. Finally, Dr Saag and Dr Freedman address the acute setting of treating rabies exposures from bats and other wild animals.0:00 – Introduction1:11 – Overview of surveillance networks and current areas of concern4:01– Discussion of mpox outbreaks including a new clade in the Democratic Republic of the Congo7:10 – Risk of H5N1 human transmission 10:07 – Update on Marburg virus disease 12:22 – Current status of Ebola disease and availability of monoclonal antibodies for treatment15:53 – Overview of outbreaks in the Caribbean: dengue fever and chikungunya 25:08 – Update on Zika virus26:36 – Discussion of how to clinically address cases of emerging viruses like Oropouche virus29:50 – How to prevent and treat rabies exposures from bats and other animals__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Rajesh Gandhi of Harvard Medical School and Massachusetts General Hospital about the new IAS-USA recommendations for HIV treatment and prevention. Dr Gandhi is the Chair of the guidelines panel, which published its recommendations in the Journal of the American Medical Association on December 1, 2024. Dr Gandhi and Dr Saag discuss the process by which the updated guidelines were created and provide an update on what's new in the current edition. They address other important topics like how to treat patients with opportunistic infections, guidance on when to change therapy, and strategies for preventing HIV acquisition. Finally, Dr Gandhi makes recommendations for those using the guidelines, especially those using them for the first time.0:00 – Introduction1:19 – Overview of the guidelines' creation process3:52– New recommendations on when to start antiretroviral therapy6:37 – New guidance on what regimens to start9:34 – Discussion of other agents like bictegravir and dolutegravir in pregnancy10:45 – How to treat patients with an opportunistic infection 14:09 – Concern about immune reconstitution inflammatory syndrome (IRIS)16:33 – Guidance on when to change therapy and providing support21:18 – How do the guidelines help people stay healthy – management of cancer, cardiovascular risk, and weight gain24:41 – Discussion on prevention of HIV and sexually transmitted diseases30:19 – What could not be addressed in the guidelines33:17 – Final comments and how to use the guidelinesResources: https://jamanetwork.com/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Kenneth Sherman of Massachusetts General Hospital and Harvard Medical School about the possibility of a cure for hepatitis B. The World Health Organization estimates that 254 million people were living with chronic hepatitis B globally in 2022. Dr Saag and Dr Sherman discuss the lifecycle of hepatitis B including the role that covalently closed circular DNA (cccDNA) plays in the hepatitis B virus (HBV) replication cycle. Dr Sherman defines functional cure and provides an overview of the most promising cure strategies. They also discuss whether antiretroviral drugs like tenofovir, used in the treatment of HIV, can contribute toward a functional cure of hepatitis B. Dr Sherman discusses other strategies like capsid assembly modulators (CAMs), monoclonal antibodies, and toll-like receptor (TLR) agonists. Finally, they discuss the effectiveness of the hepatitis B vaccine in prevention and look forward to the future by considering a timeline for a cure based on the status of ongoing clinical trials. 0:00 – Introduction1:23 – Overview of the lifecycle of hepatitis B 5:29 – Discussion of the most promising cure strategies7:11 – Defining functional cure10:56 – The role of drugs like tenofovir in a functional cure 13:39 – Targets that can affect viral production 16:04 – Potential of capsid assembly modulators (CAMs)18:03 – Other strategies like immune modulators and monoclonal antibodies22:29 – Interest in toll-like receptor (TLR) agonists and therapeutic vaccines24:32 – Outlook for the future and the effectiveness of a hepatitis B vaccine in prevention __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Jason Zucker of Columbia University and the New York City STD Prevention Training Center about mpox and the mpox outbreak. Dr Saag and Dr Zucker discuss the 2 clades of mpox, how it is transmitted, and which clade is associated with the most recent mpox outbreak. They also discuss how to test for mpox and how people with HIV present with mpox based on their HIV viral load. Dr Zucker gives a detailed update on the STOMP (Study of Tecovirimat for Human Mpox Virus) trial that evaluates the efficacy of the antiviral tecovirimat, also known as TPOXX, for the treatment of mpox. They also address the role of vaccination in mpox, its uptake and efficacy. Finally, Dr Zucker offers his perspective on how practitioners and public health officials can address ongoing mpox outbreaks in the US and globally, including a second public health emergency of international concern that was declared in the Democratic Republic of the Congo and surrounding countries in August by the World Health Organization (WHO).0:00 – Introduction1:25 – Description of mpox and its 2 clades2:07 – Overview of the current mpox outbreak3:11 – Mpox transmission4:29 – Mpox in people with HIV6:35 – Testing for mpox9:05 – The STOMP study, enrollment, and effectiveness of tecovirimat15:58 – The role for vaccination for mpox and who should receive it20:38 – Outlook for the future__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Jennifer Kates of KFF to compare and contrast health care policies from different sides of the aisle. Dr Kates provides an update on the Patient Protection and Affordable Care Act (ACA) and efforts to repeal the healthcare program in the United States. Dr Saag and Dr Kates also discuss the status of Medicaid expansion in the US and the impact of access to care in states where Medicaid has been expanded. They also discuss the impact of the Ryan White HIV/AIDS Program on healthcare for people with HIV and the long-term outlook for funding for the program. In addition, there is a detailed overview and outlook of funding for the 340B Drug Pricing Program that allows eligible hospitals and other healthcare organizations to purchase outpatient drugs at a discount from pharmaceutical manufacturers. Finally, Dr Saag and Dr Kates discuss the erosion of trust in science and public health officials in the US and reasons to be optimistic for the future.0:00 – Introduction1:15 – Update on the ACA3:19 – Discussion of efforts to repeal the ACA5:32 – Status of Medicaid expansion in the US8:56 – Overview of access to HIV care through Ryan White 10:37 – Access to health insurance coverage through Ryan White 12:31 – What is 340B funding?15:45 – Possible pressures on 340B funding 17:45 – Outlook for Ryan White funding and availability of PrEP in the program21:34 – Discussion of the erosion of trust in science and public health 26:42 – Outlook for the future__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

This episode of Going anti-Viral features an IAS–USA Dialogue titled "Latest Update on Urgent Viral Outbreaks," a panel discussion held on October 4, 2024. Dr Carlos del Rio from Emory University serves as moderator and welcomes 3 distinguished panelists: Dr Yvonne Maldonado from Stanford University, Dr Peter Chin-Hong from the University of California San Francisco, and Dr Paul Sax from Brigham and Women's Hospital. The episode covers various pressing topics, including updates on COVID-19, avian flu, mpox, and other viral diseases. Discussions touch on vaccines, their effectiveness, public health approaches, and current research.0:00 – Introduction and overview of ongoing viral outbreaks3:59 – Update on respiratory viruses and vaccination – seasonal flu, RSV, and COVID-1912:17 – Discussion of monoclonal antibody treatment for COVID-1914:15 – Update on the use of Paxlovid for COVID-1918:48 – COVID-19 vaccination – protein vaccines vs. mRNA vaccines22:48 – Update on pertussis28:54 – Discussion of seasonal influenza and vaccination32:55 – Effectiveness of shingles and RSV vaccines 35:57 – Discussion of vaccination during pregnancy40:02 – Audience questions43:04 – Update on H5N1 (avian flu) outbreak52:00 – Update on Marburg virus outbreak in Rwanda55:43 – Discussion of mpox outbreak in central Africa59:29 – Concluding remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Carolyn Chu and Dr Lealah Pollock from the University of California San Francisco about the National Clinician Consultation Center (NCCC). The NCCC offers guidance to health care practitioners on HIV, hepatitis, and substance use. Dr Chu and Dr Pollock discuss the most common questions asked by clinicians to the NCCC warm line such as: infant feeding by people with HIV, antiretroviral treatment (ART) for pregnant people with HIV, and the use of long-acting antiretroviral drugs. They also discuss how they respond to questions about the latest developments in preexposure prophylaxis (PrEP) care, care for people with sexually transmitted infections (STIs), and health care practitioner exposures. Finally, they share their thoughts about working for the NCCC and the service they offer to US-based clinicians. 0:00 – Introduction1:31 – History and overview of the services provided by the NCCC 4:31 – A common question – infant feeding in people with HIV10:03 – ART for pregnant people with HIV13:53 – Questions about long-acting antiretroviral drugs16:55 – Interpretation of resistance-associated mutations18:30 – The NCCC warm line service model20:34 – Questions about administering PrEP and impact of recent developments in PrEP research26:08 – Questions about postexposure prophylaxis (PEP) for STIs27:25 – Recommendations for health care practitioner exposures29:17 – Final thoughts and closing remarks Resources:Contact the National Clinician Consultation Center (NCCC):https://nccc.ucsf.edu/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Sandra Springer from the Yale School of Medicine about the substance use disorder epidemic. Dr Springer describes the history of the epidemic and the recent crisis of overdose deaths in the United States. She talks about the increase in overdose deaths since 1999 due to prescription opioids. Dr Saag and Dr Springer review how HIV practitioners can manage patients with substance abuse disorder, including a discussion of how to manage patients undergoing withdrawal. Finally, they address harm reduction strategies available to practitioners and new data showing a reduction in overdose deaths, providing long-term hope for the effectiveness of these strategies. But they note that more research, funding, and outreach is needed to meet the risks that opioid and non-opioid substances pose in the future.0:00 – Introduction1:22 – Magnitude of the substance use disorder epidemic2:31 – Factors that led to the increase in deaths after 19993:54 – Background on widespread fentanyl use 5:22 – Impact of prescription opioids for chronic pain management on addictions7:52 – HIV healthcare practitioners' role in managing patients with substance use disorders10:15 – Management of withdrawal, including long-term management options18:33 – Harm reduction strategies and the use of naloxone to prevent overdose deaths23:04 – Review of new data showing reduction in overdose deaths in the United States24:19 – Closing remarks and expectations for the next 10 yearsIAS–USA resources on substance use disorders: -- MATE Act CME - https://www.iasusa.org/dea-compliant-cme-resource-center/-- Fellow Resources: https://www.iasusa.org/fellow-student-resources/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Andrew Pavia from the University of Utah about influenza A, specifically the H5N1 strain. Dr Pavia describes the progression of H5N1 and its recent impacts on poultry and other animal populations, including an overview of a recent outbreak among dairy cattle and whether there is a risk to humans exposed on farms and the milk supply at large. They discuss how influenza vaccines are determined each year and the timing of when best to recommend vaccination. They describe treatment options for influenza and their effectiveness against H5N1. Finally, they address public health measures taken during influenza outbreaks and the COVID-19 pandemic, offering lessons learned for future influenza outbreaks in humans.0:00 – Introduction1:32 – Overview of influenza2:54 – Human susceptibility to influenza5:20 –Types of influenza and evolution of H5N1 from birds to mammals9:24 – Natural history of transmission in humans12:34 – Current outbreak of H5N1 in dairy cattle and risk to the milk supply      16:48 – Overview of influenza vaccines and immunity 18:47 – Optimal time to get the influenza vaccine and combined vaccination for COVID-19 23:36 – Treatment options with onset of influenza symptoms and H5N1 is resistance  30:00 – Lessons learned from public health measures taken to protect against outbreaks of influenza and COVID-19 __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Timothy Wilkin from the University of California San Diego about the human papillomavirus (HPV) and anal cancer with options for screening, prevention, and vaccination. They provide an overview of HPV and the types of HPV that lead to cancer. They discuss screening and prevention for anal cancer at HIV and PrEP clinics. They also discuss the findings of the ANCHOR study that demonstrated that high-resolution anoscopy screening detects and prevents anal cancer caused by HPV. Finally, they review HPV vaccination, its effectiveness, and the challenges with uptake of the vaccine in the population at large.0:00 – Introduction1:32 – Overview of HPV3:01 – HPV and cancer4:43 – Screening and prevention for anal cancer at HIV and PrEP clinics9:38 – Findings of the ANCHOR study – efficacy of high resolution anoscopy in detecting anal cancer caused by HPV.11:32 – Barriers to screening and treatment15:05 – HPV vaccination - recommendations and efficacy 18:10 – Challenges with HPV vaccination uptake24:30 – Next ten years of HPV and closing remarksResources and articles:Single dose HPV vaccine articlehttps://pubmed.ncbi.nlm.nih.gov/35693874/ANCHOR trialhttps://pubmed.ncbi.nlm.nih.gov/35704479/CDC OI HPV guidelineshttps://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/humanInternational Anal Neoplasia Society (guidelines and HRA training)https://www.iansoc.org__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Paul Volberding from the University of California San Francisco about long COVID and new long COVID disability guidelines. They discuss the symptoms and causes of long COVID and where to find treatment. Dr Volberding discussed his work with the National Academy of Medicine, which recently released a report on long COVID disability guidelines. 0:00 – Introduction1:53 – What is long COVID? How does someone know if they have it? 6:22 – Risk factors and causes of long COVID11:51 – Treatments for and research on long COVID 14:14 – When is long COVID a disability? Disability recommendations from the National Academy of Medicine on long COVID19:53 – How does someone with long COVID get help?23:54 - Closing Remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Peter Chin-Hong from the University of California San Francisco to get an update on important emerging infections. They discuss the current outbreak of COVID-19 and trends in the epidemiology of the disease. They also address emerging measles cases and the underlying pathophysiology of the disease. They also discuss the impact of vaccine disinformation on the risk of measles transmissibility. Finally, they address emerging infections such as avian flu, vaccine developments, and address others like respiratory syncytial virus (RSV) and pertussis.0:00 – Introduction1:42 – Status of the current COVID-19 outbreak3:48 – Update on treatments and vaccination for COVID-19 11:53 – Overview of measles and transmissibility15:30 – Measles herd immunity and vaccine disinformation19:50 – Other emerging infections and vaccine developments23:21 – Closing thoughts __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Raphael Landovitz from the UCLA Medical School about the latest information on HIV prevention via Preexposure Prophylaxis, or PrEP. They discuss the history of PrEP and early efficacy and then move into a discussion of the evolution of PrEP from episodic dosing to longer-acting therapies. The episode also highlights recent research and how that may impact the future of PrEP dosing.0:00 - Introduction1:59 - History of Preexposure Prophylaxis, or PrEP 5:39 - Why initial PrEP regimens were not 100% effective12:01 - Discussion of episodic PrEP and 2-1-1 regimens16:22 - How longer-acting therapy has been shown to be superior to episodic dosing20:29 - LEVI syndrome - what is it?25:05 - What the future holds for PrEP 29:18 - Closing Remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 20 - The Impact of GLP-1 Receptor Agonists with Dr Suman SrinivasaIn this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Suman Srinivasa from Harvard Medical School about the impact of GLP-1 receptor agonists on diabetes and obesity. They discuss the mechanisms, benefits, and current and potential applications, including their use by people with HIV. The episode also highlights future prospects and challenges, including access to medication.00:00 Introduction01:42 Understanding GLP-1 Receptor Agonists03:19 Mechanisms and Benefits of GLP-1 Receptor Agonists05:34 Clinical Applications and Insurance Challenges09:56 GLP-1 Receptor Agonists in HIV Patients15:50 Future Prospects and Broader Applications23:37 Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

 This episode of Going anti-Viral features an IAS–USA Dialogue titled "Latest Update on Urgent Viral Outbreaks," which is a panel discussion held on June 11, 2024. Dr Paul A. Volberding from the University of California San Francisco serves as moderator and welcomes three distinguished panelists: Dr Carlos del Rio from Emory University, Yvonne Maldonado from Stanford University, and Dr Peter Chin-Hong from the University of California San Francisco. The episode covers various pressing topics, including updates on COVID-19, avian flu, MPOX, measles, and other viral diseases. Discussions touch on vaccines, their effectiveness, public health approaches, and current research.00:00 Introduction to Going Antiviral Podcast01:21 COVID-19 Current Issues and Personal Experiences06:11 Long COVID and Paxlovid Study07:59 Global Perspective on COVID-1913:59 COVID-19 Vaccination Updates23:52 Avian Flu: Current Concerns and Insights29:15 The Threat of Avian Flu29:46 Understanding H5N2 and Its Impact33:09 The Ongoing MPOX Outbreak37:02 Global Public Health Challenges49:51 Travel Vaccines and Precautions56:31 The Importance of RSV Vaccination58:14 Concluding Remarks and Resources__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 18 - CROI 2024 Insights: Future Prospects of HIV Management and Cardiovascular Health with Dr Todd Brown Recorded May 3, 2024This episode discusses the evolving landscape of HIV-related metabolic complications and cardiovascular health. Dr Michael Saag and Dr Todd Brown cover insights from CROI 2024, key studies on blood pressure management, the cardiovascular benefits of statins, and the promising role of GLP-1 receptor agonists in treating diabetes, obesity, and cardiovascular disease in people with HIV.00:00 Introduction01:56 Blood Pressure Management in HIV09:56 The Impact of Statins on Cardiovascular Health18:07 The Revolutionary Role of GLP-1 Receptor Agonists in HIV Management27:01 Looking Ahead: The Future of HIV Treatment and Management29:21 Closing Remarks and Future Directions__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 17 - CROI 2024 Insights: Progress and Challenges in HIV Antiretroviral Therapy with Dr Barbara Taylor Recorded May 2, 2024 This episode of Going anti-Viral with Dr Michael Saag hosts Dr Barbara Taylor. They discussed topics covered at CROI 2024, including the 95-95-95 goal, long-acting antiretroviral therapies, mental health challenges in HIV care, and the potential for long-acting treatments in other viral diseases like hepatitis C.  00:00 Introduction and Remembering Dr Scott M. Hammer 00:27  CROI 2024 Highlights 02:55 Exploring the 95-95-95 Goal and Challenges in HIV Epidemic Control 09:01 Innovations in Long-Acting Antiretroviral Therapies 14:11 Advancements in Hepatitis C and B Therapies 16:51 COVID-19 Treatments and Resistance Concerns 19:26 Addressing Mental Health in HIV Care__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 16 -  Insights on HIV Cure by Stem Cell Transplant with Dr Ravindra Gupta Recorded Live at CROI 2024 on March 3, 2024 In this episode of Going anti-Viral, Dr Michael Saag hosts Dr Ravindra Gupta. Dr Gupta is the infectious diseases expert who led the team that treated Adam Castillejo, also known as ‘The London Patient,' the second person known to have been cured of HIV. The discussion, recorded on March 3, 2024, at the Conference on Retroviruses and Opportunistic Infections (CROI), focused on the intricate process of finding a suitable stem cell donor, the immunologic and virologic considerations around the transplant process, and the collaborative medical team effort involved.  00:00 Introduction 00:30 The London Patient 03:05 Finding the CCR5∆32 Stem Cell Match 04:21 Clinical Challenges on the Transplant Journey 06:58 Post-Transplant Monitoring and Milestones 15:53 Reflecting on the Journey 18:51 Closing Thoughts and Acknowledgments__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

In this episode of Going anti-Viral, host Dr Michael Saag interviews Adam Castillejo, known as the London patient, who is the second person to have been cured of HIV infection. The discussion, recorded on March 3, 2024, at The Conference on Retroviruses and Opportunistic Infections (CROI), touches on Adam's initial HIV diagnosis in London during the early 2000s, the societal stigma and personal impact of the diagnosis, and his dual battle with HIV and cancer. Adam shares the complex journey of his treatment, including the failure of initial interventions and the ultimate success of a bone marrow transplant from a donor with a CCR5 delta 32 mutation, leading to his cure of HIV and cancer. The conversation delves into the technical aspects of bone marrow transplant, the emotional and physical challenges Adam faced during recovery, and the continued stigma he experiences even post-cure. The episode reflects on the broader implications of Adam's story for HIV research and societal perceptions of the disease.00:00 Introduction01:10 Adam's Early Struggle with HIV Diagnosis02:46 Confronting Stigma and Finding Support05:26 The Battle Against Cancer and Mental Health Challenges08:35 The Turning Point: Bone Marrow Transplant15:14 The Journey of Recovery17:29 Life After the Cure22:37 Concluding Thoughts__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 14 - HIV Treatment with Long-Acting Injectables with Dr Aadia Rana Recorded Live at CROI 2024 on March 4, 2024In this episode, Dr Michael Saag and Dr Adia Rana discuss a breakthrough study on using a long-acting injectable HIV treatment with conditional economic incentives for individuals who were unable to take oral therapy. Presented at CROI 2024, the study's positive outcomes offer an effective option for certain individuals with no other options for continuing oral antiretroviral therapy.For further reading, please visit the link below.Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel 00:00 Introduction to the Podcast and Guest 00:50 Exploring Adherence Challenges and Study Insights 03:27 The Evolution of HIV Treatment: From Oral to Injectable Therapies 10:59 Study Results: A New Alternative for Select Individuals with Limited Treatment Options 16:05 Navigating Real-World Applications and Ethical Considerations 21:08 Reflecting on the Journey and Looking Ahead 25:21 Closing Thoughts and Future Directions__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 13 -  Advancements in STI Prevention: Insights from Dr Jean-Michel Molina Recorded Live at CROI 2024 on March 3, 2024In this episode of Going anti-Viral, Dr Michael Saag and Dr Jean-Michel Molina discuss recent developments in STI prevention, focusing on doxycycline as post-exposure prophylaxis (DoxyPEP) and the evaluation of a meningococcal vaccine for gonorrhea prevention in the ANRS Doxyvac trial. Recorded at CROI 2024, Dr Molina shares insights from clinical trials, including challenges with data analysis and implications for future STI prevention and vaccine research.00:00 Introduction to the Podcast and Guest 00:30 Innovative Approaches in Clinical Care with Dr Jean-Michel Molina00:54 Exploring the Impact of Doxycycline and Vaccines on STIs01:50 Challenges and Insights from Clinical Trials04:29 The Journey from Interim Analysis to Final Results09:27 Addressing Data Discrepancies21:05 Future Directions in STI Prevention and Vaccine Research26:46 Closing Thoughts and the Importance of Trustworthy Research__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 12 - New Study on Treatments for Non-Alcoholic Fatty Liver Disease in People With HIV With Dr Jordan Lake Recorded Live from CROI 2024In this episode, Dr Michael Saag speaks with Dr Jordan Lake live from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). They discuss the prevalence of non-alcoholic fatty liver disease (NAFLD) among people with HIV and explore the effectiveness of the GLP-1 receptor agonist semaglutide, commonly used to treat diabetes and aid in weight loss, to treat NAFLD. Future areas of research are considered, including maintenance strategies post-weight loss and a placebo-controlled version of the study.00:02 Introduction and Welcome00:44 Discussion on Non-Alcoholic Fatty Liver Disease in People With HIV01:56 Role of HIV in Non-Alcoholic Fatty Liver Disease02:43 Understanding the Inflammation and Fat Accumulation in the Liver04:38 Exploring the Impact of Nucleoside Therapy on Non-Alcoholic Fatty Liver Disease06:37 Potential Treatments for Non-Alcoholic Fatty Liver Disease07:35 The Role of Semaglutide in Treating Non-Alcoholic Fatty Liver Disease13:36 The Importance of Routine Assessment for Non-Alcoholic Fatty Liver Disease15:37 Exploring New Drugs for Treating Non-Alcoholic Fatty Liver Disease18:49 The Challenges and Future Directions in Non-Alcoholic Fatty Liver Disease Research22:25 Conclusion and Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 11 - Innovations in Vaccine Research: Single Cell Immunity Development With Dr Fabian Otte Recorded Live from CROI 2024In this podcast episode, Dr Michael Saag converses with Dr Fabian Otte, a molecular biologist at the University of Basel in Switzerland, live from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). Dr Otte shares insights into the ongoing development of an innovative SARS-CoV-2 vaccine that employs a single-cell immunity development approach. Highlighting its potential benefits, such as broader and longer-lasting immunity compared with mRNA vaccines. This pioneering vaccine research might also extend to other RNA viruses in the future. 00:02 Introduction to the Podcast and Guest 00:28 Discussion on the Development of Next-Generation SARS-CoV-2 Vaccines 00:50 Exploring a Single-Cell Immunity Approach 01:10 Understanding the Vaccine Development Process 02:42 The Potential of the New Vaccine 03:13 Challenges and Advantages of the New Vaccine 05:07 The Impact of the Vaccine on Immune Response__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 10 - Harnessing the Power of Bacteriophages With Dr Robert SchooleyIn this podcast episode, host Dr Michael Saag speaks with Dr Robert “Chip” Schooley, a distinguished Professor of Medicine in the Division of Infectious Diseases and Global Public Health at the University of California San Diego. They discuss the revolutionary potential of bacteriophages, viruses that can infect and kill bacteria. They detail the research efforts and case studies involved in understanding the potential deployment of bacteriophages as a medical treatment. The discussion also highlights the necessity for clinical trials and future research involving genetically engineered phages.00:02 Introduction and Guest Profile01:51 The Growing Problem of Antimicrobial Resistance02:55 Understanding Bacteriophages04:21 The History and Use of Bacteriophages in Labs05:45 The Role of Bacteriophages in Molecular Biology11:43 The Journey of Treating a Patient with Bacteriophages19:19 The Future of Bacteriophage Therapy31:05 Closing Remarks and Podcast Outro__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 9 - Understanding The Implementation of Doxycycline Post-Exposure Prophylaxis (DoxyPEP) and Addressing Sexually Transmitted Infections with Dr Annie Luetkemeyer In this episode of Going anti-Viral, Dr Michael Saag has an insightful discussion with Dr Annie Luetkemeyer, a professor of medicine in the Division of HIV, Infectious Diseases, and Global Medicine at Zuckerberg San Francisco General at the University of California San Francisco.  Centering around the state of sexually transmitted infections in the United States, rising cases, strategies for control, and the promising role of doxycycline post-exposure prophylaxis (DoxyPEP)00:02 Introduction to the Podcast01:31 Discussion on the State of Sexually Transmitted Infections05:21 Exploring the Concept of Post-Exposure Prophylaxis07:19 Understanding the Implementation of DoxyPEP10:23 Effectiveness of DoxyPEP17:41 Potential Side Effects and Concerns of DoxyPEP22:37 Future Prospects of DoxyPEP in STI Prevention28:04 Conclusion and Final Thoughts28:46 Podcast Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 8 - A Historical Overview of The HIV/AIDS Epidemic, Prevention and Intervention Methods, and Future Strategies with Dr Susan BuchbinderIn this episode of the Going anti-Viral podcast, host Dr Michael Saag speaks with Dr Susan Buchbinder, a professor of medicine, epidemiology, and biostatistics at the University of California, San Francisco. They discuss the HIV/AIDS epidemic, tracing its history from its rise in the early 80s to its current status. The conversation covers the efficacy of different preventive and treatment strategies, such as community engagement, behavioral changes, condom use, pre-exposure prophylaxis (PrEP), and the prospects of a future HIV vaccine.00:02 Introduction to the Podcast00:31 Guest Introduction: Dr Susan Buchbinder01:10 History of the HIV Epidemic05:01 The Role of Community in HIV Prevention06:30 Prevention and Interventions07:40 The Importance of HIV Testing10:28 The Revolution of PrEP in HIV Prevention12:42 The Challenges in Ending the HIV Epidemic22:18 The Future of HIV Prevention24:55 Conclusion and Final Thoughts__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 7 - A Conversation With Dr Katelyn K. Jetelina About Her Journey in The Field of Epidemiology, The Initial Handling of The COVID-19 Pandemic, The Spreading of Misinformation, And The Urgent Need to Rebuild Public Trust in Health Infrastructure.In this episode of Going anti-Viral, Dr Michael Saag speaks to epidemiologist Dr Katelyn K. Jetelina, co-founder of The Health Trust Initiative, and Senior Scientific Advisor to several government and non-profit agencies, including the White House, Centers for Disease Control and Prevention, and Resolve to Save Lives. The conversation, dated January 8, 2024, revolves around Dr Jetelina's journey in the field of epidemiology, the initial handling of the COVID-19 pandemic, the spreading of misinformation, and the urgent need to rebuild public trust in health infrastructure. They also touch on the role of Artificial Intelligence (AI) in rapidly spreading misinformation for profit, and its potential to disseminate correct information. Dr Jetelina suggests that empowering community leaders with accurate scientific information and leveraging technologic innovations can play a key role in improving the public health system.00:02 Introduction and Guest Presentation01:09 Dr Jetelina's Journey Into Epidemiology03:19 Understanding the Transmission of COVID-1906:39 The Impact of COVID-19 and the Role of Public Health Officials 11:00 The Challenge of Misinformation and Disinformation21:49 Addressing the Future: Preparing for the Next Pandemic26:10 Conclusion and Final Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Episode 6 - A Conversation With Dr Anthony Fauci on His Career And His Role in the Responses to AIDS and COVID-19. Recorded December 14, 2023 Dr Michael Saag hosts Dr Anthony Fauci on this episode of the Going anti-Viral podcast, discussing Dr Fauci's career journey, his involvement in AIDS research, and his contribution towards managing other viral diseases. The conversation particularly focuses on the initial response to AIDS, the response to the COVID-19 pandemic, the vaccine development process, and the challenges and successes encountered. The podcast also highlights the significant shift in activism around public health crises, contrasting the constructive role of AIDS activists with the destructive anti-science activism faced during COVID-19. 00:02 Introduction and Background00:42 Dr Anthony Fauci's Early Life and Career02:07 Beginning of the AIDS Story02:12 First Encounter with AIDS and Initial Response03:34 The Turning Point in AIDS Research04:16 Building the AIDS Research Team12:04 The Role of Activism in AIDS Research17:06 The Emergence of COVID-1917:55 The Development of the COVID-19 Vaccine25:58 The Challenges of Anti-Science Activism in the COVID-19 Era29:29 The Future of Public Health Communication30:28 Conclusion and Reflections__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Episode 5 - An In-depth Discussion on Syphilis with Dr Meredith Clement, Associate Professor at Louisiana State University Health Sciences Center. This special episode was recorded live from the 2023 Ryan White HIV/AIDS Program CLINICAL CONFERENCE in Portland, OR, on December 4th, 2023.In this special episode of Going anti-Viral, recorded live from the 2023 Ryan White HIV/AIDS Program CLINICAL CONFERENCE in Portland, OR, Dr Michael Saag speaks with Dr Meredith Clement, Associate Professor at Louisiana State University Health Sciences Center. They discuss the history and increasing prevalence of syphilis, the contributing factors to its resurgence, and its various stages. Dr Clement also highlights the current challenges in syphilis treatment, such as medication shortages and the need for rigorous screenings during prenatal care.00:08 Introduction and Welcome00:57 Discussing the History and Prevalence of Syphilis01:40 Understanding the Decline of Syphilis in the 1990s02:21 Current State of Syphilis Cases and Demographics03:29 Challenges in Prenatal Care and Congenital Syphilis07:05 Understanding the Stages of Syphilis09:47 Diagnosis and Testing for Syphilis13:53 Treatment Options for Syphilis15:53 Challenges and Future Directions in Syphilis Treatment22:41 Conclusion and Final Thoughts__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Episode 4 - A Deep Dive into Vaccine Development with Dr Richard Koup, Deputy Director Chief, Immunology Laboratory Vaccine Research Center, NIAID, NIH. This special episode was recorded live from the 2023 Ryan White CLINICAL CONFERENCE in Portland, OR, December 2nd, 2023In this special episode of Going anti-Viral, recorded live from the 2023 Ryan White CLINICAL CONFERENCE in Portland, OR, we explore the challenges and progress in developing vaccines for HIV and COVID-19. Dr Saag discusses with Dr Richard Koup, Deputy Director Chief, Immunology Laboratory Vaccine Research Center, NIAID, NIH, about vaccine development for HIV and its associated challenges and how pre-existing knowledge of similar viruses expedited COVID-19 vaccine development. The conversation also touches upon cellular immunity, broadly neutralizing antibodies, and the potential future of HIV vaccine development.00:08 Introduction and Welcome00:44 Interview with Dr Richard Koup01:05 The History of HIV Vaccine Development02:26 The Challenges of HIV Vaccine Development06:33 The Role of Broadly Neutralizing Antibodies in HIV Vaccine Development14:30 The Potential of Cellular Immunity in HIV Vaccine Development16:08 The Miraculous Development of the COVID-19 Vaccine26:37 The Future of HIV Vaccine Development28:13 Conclusion and Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Episode 3 - Latest Update on Emerging and Reemerging Urgent Viral Outbreaks, Including COVID-19, MPOX, and Flu. October 2023  In today's episode of Going anti-Viral, we present a recent dialogue from October 19th, 2023, with special guest Katelyn K. Jetelina, MPH, PhD. Dr Jetelina is an epidemiologist, data scientist, and author of the popular newsletter "Your Local Epidemiologist (YLE)". She joined moderator Paul Volberding, MD, and discussants Peter Chin-Hong, MD, and Carlos del Rio, MD, for a lively discussion on the latest hot-button issues in the field of infectious diseases.Key conversations focus on the state of the COVID-19 pandemic, the role of vaccines and the growing issues related to insufficient data when tracking and treating viral infections. The discussion further extends to examine the political backlash that threatens institutional trust, pushing for a stronger approach that involves community-based contributions to conquering infectious diseases.00:08 Introduction and Guest Presentation01:16 Guest Introductions and Backgrounds04:48 Discussion on Current Infectious Disease Trends09:14 The Role of Data in Tracking Disease Trends12:30 The Politics of Public Health Data16:41 The Impact of Politics on Vaccination16:54 Vaccination Discussion: COVID-19, Influenza, and RSV26:20 Influenza Season Discussion28:24 Discussion on Vaccination Coverage and Data Collection30:30 The Importance of Vaccination Timing and Convenience31:33 Understanding RSV in Adults and Its Diagnosis32:28 The Importance of Testing and the Impact of COVID-19 on Testing Practices33:13 The Challenge of Distinguishing Between Different Respiratory Infections34:27 Discussion on Influenza Vaccines and Their Effectiveness36:08 The Importance of Vaccination and Addressing Vaccine Hesitancy43:55 The Future of Vaccines09:10 Addressing the Challenges of Misinformation and Trust in Public Health__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Episode 2 - Latest Update on Urgent Virus Outbreaks, August 2023 Dialogue on Urgent Viral Diseases     This episode of Going anti-Viral features an IAS–USA Dialogue titled "Latest Update on Urgent Virus Outbreaks," which is a panel discussion held on August 1, 2023. Dr Paul A. Volberding from the University of California San Francisco serves as the moderator and welcomes three distinguished panelists: Dr Carlos del Rio from Emory University, Yvonne Maldonado from Stanford University and Dr Michael Saag from the University of Alabama Birmingham. discuss recent developments in COVID-19, MPOX, RSV, and HIV. This includes the the paradigm-shifting results of the REPRIEVE study, current hurdles in COVID-19 vaccination and antiviral treatment, and trends in RSV and MPOX. They also discuss the overall impact of COVID-19 on education and child development. 00:08 Introduction and Panel Discussion Overview 01:56 Discussion on the REPRIEVE Study 05:59 COVID-19 Updates and Vaccination Challenges 13:35 The Role of Antivirals in COVID-19 Treatment 20:39 Future of COVID-19 Vaccines and Age Group Considerations 27:20 The Importance of Transparency28:18 The Need for Open Discussions on COVID-19 Vaccines 29:47 The Existential Threat to Science-Based Medicine 31:49 The Challenge of Testing for RSV 33:11 The Potential Impact of RSV Vaccines 36:45 The Ongoing Struggle with Long COVID-19 42:46 The Increasing Cases of MPOX 48:27 The Tragic Impact of the Pandemic on Education 53:42 The Importance of In-Person Interactions 54:10 Closing Remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Episode 1 - 40 Years Later: Looking Back at the Beginning of the HIV/AIDS EpidemicIn this episode of Going anti-Viral, we revisit a panel discussion titled "40 Years Later: Looking Back at the Beginning of the HIV/AIDS Epidemic," sponsored by the IAS–USA. Dr Gerald Friedland moderates a panel of key medical figures who served at the frontlines of the HIV/AIDS epidemic during its early years. The panel, consisting of Dr Kathryn Anastos, Dr Donna Futterman, Dr Sheldon Landesman, and Dr Fred Valentine discusses their experiences, the systemic responses, and the stigma associated with the disease. They contemplate on how the lessons learned from HIV are relevant to the current COVID-19 pandemic and the potential pandemics that may come in the future.The discussion took place on June 13, 2022, at the Scott M. Hammer Annual Update on HIV Management in New York City.00:00 Introduction and Overview of the Podcast00:37 Panel Discussion: Reflecting on the Early Days of the HIV Epidemic01:20 Panelists Share Their Personal Experiences and Challenges02:29 The Impact of HIV on Medical Professionals and Their Careers03:01 The Spread of HIV in Different New York City Boroughs03:45 Panelists' Current Roles and Their Initial Encounters with HIV06:01 The Struggle with Internalized Homophobia in HIV Patients06:26 The Evolution of HIV Treatment and the Reaction of Medical Providers07:44 The Emotional Impact of the HIV Epidemic20:06 The Challenges of Creating a System of Care for HIV Patients21:23 The Stigma and Misunderstandings Surrounding HIV40:29 The Role of Activism in the Fight Against HIV41:35 Institutional Responses to the HIV Epidemic43:21 Challenges in Pediatric Care for HIV Patients44:10 Stigma and Discrimination in Healthcare44:47 International Efforts in HIV Testing47:01 Safety Measures in HIV Research Labs48:43 Health and Hospitals Corporation's Role in HIV Care50:01 The Impact of HIV on Medical Education and Training54:11 The Role of Activism in the HIV/AIDS Response55:40 Lessons from HIV for Future Pandemics57:16 The Response of the Medical Community to HIV58:21 The Importance of Addressing Social Determinants of Health01:00:08 The Future of HIV Research and Care01:06:34 Closing Remarks and Reflections__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Introducing Going anti-Viral, the podcast of the IAS–USA, a professional continuing medical education organization focused on HIV and other viral diseases. I'm Dr Michael Saag, professor emeritus of medicine and infectious diseases at the University of Alabama at Birmingham and volunteer member of the IAS–USA Board of Directors.  Join us as we interview experts in viral medicine about their area of specialty and current developments in the field. Other episodes are drawn from the IAS-USA vast catalogue of panel discussions, Dialogues, and various meetings and conferences.  Going anti-Viral is a podcast series for clinicians, produced by the International Antiviral Society–USA. The IAS–USA is a not-for-profit professional organization committed to improving the treatment, care, and quality of life for people with or at risk for HIV or other viral infections and their complications through balanced education and information. This podcast is intended as a technical source of information for specialists in this field, but we hope anyone listening will enjoy learning more about the state of modern medicine around viral infections and their consequences.__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.